Predicting response to multidrug regimens in cancer patients using cell line experiments and regularised regression models

Steffen Falgreen(Chr. Hansen (Denmark)), Martin Bøgsted(Chr. Hansen (Denmark)), Zijun Y. Xu‐Monette(Duke University), Tarec Christoffer El‐Galaly(Aalborg University Hospital), Mette Nyegaard(Statens Serum Institut), Alexander Schmitz(Chr. Hansen (Denmark)), Maria Bach Laursen(Chr. Hansen (Denmark)), Hans Erik Johnsen(Herlev Hospital), Julie Støve Bødker(Chr. Hansen (Denmark)), Karen Dybkær(Aalborg University Hospital), Malene Krag Kjeldsen(Chr. Hansen (Denmark)), Ken H. Young(Duke Medical Center)

BMC Cancer

April 7, 2015

10.1186/s12885-015-1237-6

Cited by 65

Related Papers

Common variants conferring risk of schizophrenia

|Nature|2009|1.7k

MYC/BCL2 protein coexpression contributes to the inferior survival of activated B-cell subtype of diffuse large B-cell lymphoma and demonstrates high-risk gene expression signatures: a report from The International DLBCL Rituximab-CHOP Consortium Program

|Blood|2013|683

Immunohistochemical Double-Hit Score Is a Strong Predictor of Outcome in Patients With Diffuse Large B-Cell Lymphoma Treated With Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone

|Journal of Clinical Oncology|2012|682

PD-1 expression and clinical PD-1 blockade in B-cell lymphomas

|Blood|2017|429

Complete Surgical Excision Is Essential for the Management of Patients With Breast Implant–Associated Anaplastic Large-Cell Lymphoma

|Journal of Clinical Oncology|2015|418